ljc 10627 has been researched along with Cronobacter Infections in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Livermore, DM; Mushtaq, S | 1 |
| Ikawa, K; Ikeda, K; Morikawa, N; Ohge, H; Sueda, T | 1 |
| Derendorf, H; Ikawa, K; Ikeda, K; Morikawa, N; Murakami, Y; Nakashima, A; Ohge, H; Sueda, T | 1 |
3 other study(ies) available for ljc 10627 and Cronobacter Infections
| Article | Year |
|---|---|
Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.
Topics: Anti-Infective Agents; beta-Lactam Resistance; Enterobacteriaceae; Enterobacteriaceae Infections; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Thienamycins | 2013 |
Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation.
Topics: Abdomen; Adult; Aged; Anti-Bacterial Agents; Ascitic Fluid; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Laparotomy; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Surgical Wound Infection; Thienamycins | 2008 |
Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bile; Biliary Tract; Dose-Response Relationship, Drug; Drug Administration Schedule; Enterobacteriaceae; Enterobacteriaceae Infections; Female; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2011 |